An observational study in Sleep Apnea, Obstructive, sponsored by University Hospital, Angers. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-01-16.
Sponsored by University Hospital, Angers · Observational
Obstructive sleep apnea (OSA) is independently associated with cardiovascular diseases, including myocardial infarction and stroke. OSA may promote atherosclerosis risk factors such as hypertension, diabetes and dyslipidemia and may have direct proatherogenic effects on the vascular wall. A growing number of studies have recently focused on the role of microparticles (MPs) in the atherogenic process. Case-control studies have shown that platelet-, endothelial- and leukocyte-derived MP levels are increased in OSA and that leukocyte-derived MP are released during the night in OSA. Furthermore, experimental evidence shows that MPs from OSA patients induce endothelial dysfunction.
The objective of this prospective study is to evaluate the impact of increased levels of leukocyte derived MPs on the cardiovascular outcomes in patients with prevalent cardiovascular diseases investigated for OSA.
MPs are small plasma membrane vesicles that can be released by a variety of vascular or blood cells and that contain membrane and cytosolic elements. Case-control studies have shown that platelet-, endothelial- and leukocyte-derived MP levels are increased in OSA. Experimental evidence shows that MPs from OSA patients induce endothelial dysfunction, inflammation, and vascular hyperreactivity when injected to mice.
The impact of increased levels of MPs on the cardiovascular prognosis in OSA patient with prevalent cardiovascular diseases in unknown.
Patient with prevalent cardiovascular diseases referred to a sleep clinic for suspected OSA.
Exclusion Criteria:
death from any cardiovascular cause
outcomes assessed every year at the follow up visit or by calling the primary care physician
Time frame: first event within 5 years after inclusion
myocardial infarction (acute infarct or silent myocardial infarction or unstable angina)
outcomes assessed every year at the follow up visit or by calling the primary care physician
Time frame: first event within 5 years after inclusion
cerebrovascular infarction (stroke or transient ischemic attack)
outcomes assessed every year at the follow up visit or by calling the primary care physician
Time frame: first event within 5 years after inclusion
hospitalization for heart failure
outcomes assessed every year at the follow up visit or by calling the primary care physician
Time frame: first event within 5 years after inclusion
Plan to share: Undecided
No publications or documents are linked to this record.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University Hospital, Angers